Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. [electronic resource]
Producer: 20140505Description: 3320-6 p. digitalISSN:- 1527-7755
- Aged
- Antineoplastic Agents -- adverse effects
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Chemotherapy, Adjuvant
- Disease-Free Survival
- Double-Blind Method
- Female
- Gefitinib
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Neoplasm Staging
- Placebos
- Prospective Studies
- Quinazolines -- adverse effects
- Survival Rate
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.